Drugs / ML-246
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04222413 | Oct 2020 → Dec 2027 expected | breast cancer, childhood malignant neoplasm, colorectal neoplasm, malignant pancreatic neoplasm +1 | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ML-246 | “Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors” NCT04222413 ↗ |
| Known as | Metarrestin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04222413 ↗ |
| Modality | Small molecule | — CHEMBL4594433 ↗ |
| Route | Oral | “Participants will take metarrestin by mouth until they cannot tolerate it or stop to benefit from it.” NCT04222413 ↗ |